Skip to main content
    R

    ResMed Inc (RMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $238.23
    -1.30 (-0.54%)

    Market Cap: $33.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ResMed Inc (RMD) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    ResMed reported revenue of $5.65B for the fiscal year ended Jun 30, 2026, up 9.9% from the year before. That year, net income was $1.52B with a net margin of 26.9%, operating cash flow was $1.81B and free cash flow was $1.65B. The quarter ended Sep 30, 2026 had revenue of $1.41B and net income of $418.41M.

    Revenue and Margins

    The operating margin was 33.4% in the fiscal year ended Jun 2026, the highest of the 10 years shown. Over the 9 years to Jun 2026, revenue grew from $2.07B, a compound annual rate of 11.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$5.65B+9.9%61.1%33.4%26.9%
    Jun 2025$5.15B+9.8%59.4%32.7%27.2%
    Jun 2024$4.69B+10.9%56.7%28.2%21.8%
    Jun 2023$4.22B+18.0%55.8%26.8%21.3%
    Jun 2022$3.58B+11.9%56.6%28.0%21.8%
    Jun 2021$3.20B+8.1%57.5%28.3%14.8%
    Jun 2020$2.96B+13.4%58.1%27.4%21.0%
    Jun 2019$2.61B+11.4%57.3%22.2%15.5%
    Jun 2018$2.34B+13.2%57.0%23.2%13.5%
    Jun 2017$2.07BN/A58.1%20.6%16.6%
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, net income rose 8.6% from the year before. In the quarter ended Sep 2026, net income rose 20.0% from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue$5.65B$5.15B$4.69B$4.22B$3.58B$3.20B$2.96B$2.61B$2.34B$2.07B
    Cost of revenue$2.20B$2.09B$2.03B$1.87B$1.55B$1.36B$1.24B$1.11B$1.01B$864.99M
    Gross profit$3.45B$3.05B$2.66B$2.36B$2.02B$1.84B$1.72B$1.49B$1.33B$1.20B
    Research and development$378.29M$331.28M$307.52M$287.64M$253.57M$225.28M$201.95M$180.65M$155.15M$144.47M
    Operating income$1.89B$1.69B$1.32B$1.13B$1.00B$903.68M$809.66M$579.26M$541.83M$425.80M
    Net income$1.52B$1.40B$1.02B$897.56M$779.44M$474.50M$621.67M$404.59M$315.59M$342.28M
    EBITDA$2.11B$1.91B$1.53B$1.35B$1.19B$1.11B$978.88M$719.33M$653.25M$542.05M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.41B$1.46B$1.43B$1.42B$1.34B$1.35B$1.29B$1.28B$1.22B$1.22B$1.20B$1.16B
    Gross profit$870.57M$861.22M$890.98M$878.72M$817.66M$820.07M$766.41M$751.27M$717.22M$715.53M$692.78M$646.93M
    Operating income$452.98M$448.71M$499.81M$491.66M$446.54M$454.54M$426.27M$417.24M$387.31M$381.22M$374.58M$275.09M
    Net income$418.41M$383.43M$398.73M$392.59M$348.54M$379.70M$365.04M$344.62M$311.36M$292.24M$300.49M$208.80M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded total debt of $659.37M by $809.87M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$8.97B$8.17B$6.87B$6.75B$5.10B$4.73B$4.59B$4.11B$3.06B$3.47B
    Current assets$4.32B$3.51B$2.36B$2.37B$1.93B$1.57B$1.52B$1.15B$1.07B$1.64B
    Cash and equivalents$1.47B$1.21B$238.36M$227.89M$273.71M$295.28M$463.16M$147.13M$188.70M$821.93M
    Total liabilities$2.38B$2.21B$2.01B$2.62B$1.74B$1.84B$2.09B$2.04B$1.00B$1.51B
    Short-term debt$259.95M$9.90M$9.90M$9.90M$9.92M$12.00M$11.99M$11.99M$11.47M$214.99M
    Long-term debt$399.42M$658.39M$697.31M$1.43B$765.33M$643.35M$1.16B$1.26B$269.99M$1.08B
    Shareholder equity$6.59B$5.97B$4.86B$4.13B$3.36B$2.89B$2.50B$2.07B$2.06B$1.96B
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$8.21B$8.97B$8.78B$8.50B$8.31B$8.17B$7.57B$7.14B$7.22B$6.87B$6.81B$6.91B
    Total liabilities$2.26B$2.38B$2.29B$2.18B$2.19B$2.21B$2.02B$1.89B$2.03B$2.01B$2.18B$2.42B
    Cash and equivalents$1.01B$1.47B$1.66B$1.42B$1.38B$1.21B$932.71M$521.94M$426.36M$238.36M$237.91M$210.25M
    Shareholder equity$5.95B$6.59B$6.49B$6.32B$6.12B$5.97B$5.55B$5.25B$5.20B$4.86B$4.63B$4.48B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Jun 2026, free cash flow was 91.2% of operating cash flow. Dividends and share repurchases together came to 63.6% of it.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow$1.81B$1.75B$1.40B$693.30M$351.15M$736.72M$802.25M$459.05M$505.03M$414.05M
    Capital expenditures$156.28M$89.86M$99.46M$119.67M$134.84M$102.71M$95.33M$68.71M$62.58M$62.22M
    Free cash flow$1.65B$1.66B$1.30B$573.63M$216.31M$634.01M$706.92M$390.34M$442.44M$351.83M
    Dividends paid$349.66M$311.74M$283.61M$260.64M$245.34M$230.21M$225.40M$212.62M$199.98M$198.03M
    Share repurchases$700.04M$300.02M$150.01M$0$0N/AN/A$22.84M$53.80MN/A
    Investing cash flow-$545.20M-$200.04M-$269.78M-$1.16B-$229.92M-$158.46M-$179.86M-$1.08B-$101.82M-$81.89M
    Financing cash flow-$1.01B-$606.25M-$1.12B$422.87M-$128.36M-$764.63M-$317.29M$580.64M-$1.03B-$262.87M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$422.42M$454.63M$554.13M$339.75M$457.32M$538.77M$578.66M$308.62M$325.54M$440.11M$402.03M$272.83M
    Capital expenditures$48.74M$51.13M$33.65M$28.54M$42.97M$30.59M$20.80M$20.64M$17.84M$24.88M$21.19M$23.35M
    Free cash flow$373.68M$403.50M$520.48M$311.21M$414.36M$508.18M$557.87M$287.98M$307.70M$415.23M$380.84M$249.48M
    Last 12 quarters

    Frequently Asked Questions About RMD

    What is ResMed's annual revenue?

    ResMed reported revenue of $5.65B for the fiscal year ended Jun 30, 2026.

    How fast is ResMed's revenue growing?

    Revenue was up 9.9% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 10.2%.

    Is ResMed profitable?

    Yes. ResMed reported net income of $1.52B for the fiscal year ended Jun 30, 2026, with a net margin of 26.9%.

    How much free cash flow does RMD generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of $1.81B minus capital expenditures of $156.28M produced free cash flow of $1.65B.

    How much debt does ResMed have?

    The balance sheet dated Jun 30, 2026 reported long-term debt of $399.42M, short-term debt of $259.95M and cash and equivalents of $1.47B.